Oncoinfo· @Oncoinfo_it · X·· 13 小时前评分70
正文 · 机器翻译
#ESMO26 | Armando Orlandi 评论了 TALENT 研究在处于新辅助治疗阶段的 HR+/HER2-low 乳腺癌患者中使用 T-DXd 的结果👇
#OncoSTEPS #earlybreastcancer #eBC
40 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Oncoinfo · x.com